EGFR and non-small cell lung carcinoma: First, the synthesized Spautin-1 analogues were subjected to an EGFR-mutant NSCLC cell viability screening to determine which compounds were the most promising in terms of reducing the viability of EGFR-mutant NSCLC cells in vitro.